ITTO20110639A1 - Metodo per aumentare l'effetto di una forma attivata-potenziata di un anticorpo - Google Patents

Metodo per aumentare l'effetto di una forma attivata-potenziata di un anticorpo

Info

Publication number
ITTO20110639A1
ITTO20110639A1 IT000639A ITTO20110639A ITTO20110639A1 IT TO20110639 A1 ITTO20110639 A1 IT TO20110639A1 IT 000639 A IT000639 A IT 000639A IT TO20110639 A ITTO20110639 A IT TO20110639A IT TO20110639 A1 ITTO20110639 A1 IT TO20110639A1
Authority
IT
Italy
Prior art keywords
active
increase
effect
enhanced shape
enhanced
Prior art date
Application number
IT000639A
Other languages
English (en)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2010129298/15A external-priority patent/RU2526153C2/ru
Priority claimed from RU2010129295/15A external-priority patent/RU2531049C2/ru
Priority claimed from RU2010129290/15A external-priority patent/RU2525155C2/ru
Priority claimed from RU2010129292/15A external-priority patent/RU2523557C2/ru
Priority claimed from RU2010129294/15A external-priority patent/RU2542414C2/ru
Priority claimed from RU2010129291/15A external-priority patent/RU2525156C2/ru
Priority claimed from RU2010130358/15A external-priority patent/RU2519695C2/ru
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2010130356/15A external-priority patent/RU2542453C2/ru
Priority claimed from RU2010130355/15A external-priority patent/RU2530638C2/ru
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2011110106/15A external-priority patent/RU2523451C2/ru
Priority claimed from RU2011127059/15A external-priority patent/RU2536234C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Priority claimed from RU2011127055/15A external-priority patent/RU2536230C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Priority claimed from RU2011127053/15A external-priority patent/RU2565400C2/ru
Priority claimed from RU2011127052/15A external-priority patent/RU2503462C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of ITTO20110639A1 publication Critical patent/ITTO20110639A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
IT000639A 2010-07-15 2011-07-15 Metodo per aumentare l'effetto di una forma attivata-potenziata di un anticorpo ITTO20110639A1 (it)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
RU2010129290/15A RU2525155C2 (ru) 2010-07-15 2010-07-15 Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для комплексной терапии хронической сердечной недостаточности
RU2010129292/15A RU2523557C2 (ru) 2010-07-15 2010-07-15 Способ лечения вегетососудистой дистонии и фармацевтическая композиция для лечения вегетососудистой дистонии
RU2010129294/15A RU2542414C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
RU2010129291/15A RU2525156C2 (ru) 2010-07-15 2010-07-15 Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии
RU2010129298/15A RU2526153C2 (ru) 2010-07-15 2010-07-15 Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
RU2010129295/15A RU2531049C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы
RU2010130356/15A RU2542453C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
RU2010130355/15A RU2530638C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения органических заболеваний нервной системы, психоорганического синдрома и энцефалопатий различного генеза
RU2010130358/15A RU2519695C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011110106/15A RU2523451C2 (ru) 2011-03-17 2011-03-17 Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для лечения хронической сердечной недостаточности
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011127055/15A RU2536230C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения неврологическо-поведенческих рассторойств развития и способ лечения неврологическо-поведенческих расстройств развития
RU2011127059/15A RU2536234C2 (ru) 2011-07-01 2011-07-01 Нейротропное лекарственное средство и способ лечения органических заболеваний нервной системы, психоорганического синдрома и энцефалопатий различного генеза
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127053/15A RU2565400C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения заболеваний мочеполовой системы и способ лечения заболеваний мочеполовой системы
RU2011127052/15A RU2503462C2 (ru) 2011-07-01 2011-07-01 Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство

Publications (1)

Publication Number Publication Date
ITTO20110639A1 true ITTO20110639A1 (it) 2012-01-16

Family

ID=44863151

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000639A ITTO20110639A1 (it) 2010-07-15 2011-07-15 Metodo per aumentare l'effetto di una forma attivata-potenziata di un anticorpo

Country Status (25)

Country Link
US (3) US9308275B2 (it)
EP (1) EP2593140A2 (it)
JP (2) JP2013538186A (it)
KR (1) KR20140014059A (it)
AR (1) AR082247A1 (it)
AU (1) AU2011278038B2 (it)
BR (1) BR112013000840A2 (it)
CA (1) CA2804966A1 (it)
CZ (1) CZ2013105A3 (it)
DE (1) DE112011102358T5 (it)
DK (1) DK201370079A (it)
EA (1) EA030566B1 (it)
EE (1) EE201300006A (it)
ES (1) ES2440393R1 (it)
FI (1) FI20135143L (it)
FR (1) FR2962656A1 (it)
GB (1) GB2495884B (it)
IT (1) ITTO20110639A1 (it)
LT (1) LT5988B (it)
MX (1) MX2013000543A (it)
NO (1) NO20130222A1 (it)
NZ (1) NZ606767A (it)
PE (1) PE20130398A1 (it)
SG (2) SG187038A1 (it)
WO (1) WO2012007845A2 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011278038B2 (en) * 2010-07-15 2017-02-02 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
GB2495885B (en) * 2010-07-15 2017-11-22 Iliich Epshtein Oleg Combination pharmaceutical composition and methods of treating genitourinary system disorders
MX2013000804A (es) * 2010-07-21 2013-10-28 Oleg Iliich Epshtein Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos.
WO2012010974A2 (en) * 2010-07-21 2012-01-26 Oleg Lliich Epshtein Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
EP2450375A1 (en) 2010-11-09 2012-05-09 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3134718A (en) 1963-12-12 1964-05-26 Schering Corp Pregna-1,4-dienes and compositions containing same
US3901967A (en) 1973-09-10 1975-08-26 Union Corp Sustained release of atropine
SE393532B (sv) 1974-05-02 1977-05-16 Draco Ab Sett att framstella en farmaceutisk zinkberedning for astadkommande av en smaklig, fordragbar, peroral zinklosning innehallande ett zinkkomplex
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
SU1331508A1 (ru) 1985-08-14 1987-08-23 Киевский Кабельный Завод "Укркабель" Устройство дл пневматического массажа урогенитальной сферы человека
FI101344B1 (fi) 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US4987127A (en) 1989-01-31 1991-01-22 Dal Sirany Method of treating a virus outbreak
SU1730144A1 (ru) 1989-02-24 1992-04-30 Научный Центр По Разработке И Внедрению Современных Методов Молекулярной Диагностики Способ подавлени репродукции вирусов
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
RU2007989C1 (ru) 1991-11-12 1994-02-28 Акционерное общество "Трейдис" Способ габович подбора гомеопатических препаратов и их разовой дозы
CA2146647C (en) 1992-10-08 2009-05-05 Marc Feldmann Treatment of autoimmune and inflammatory disorders
DK140992D0 (da) 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5879677A (en) 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
RU2033784C1 (ru) 1993-05-28 1995-04-30 Индивидуальное частное предприятие "Диалог" Устройство для репродуцирования гомеопатических и изопатических препаратов
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US5629286A (en) 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
IL110035A0 (en) 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
RU2137483C1 (ru) 1995-08-02 1999-09-20 Божедомов Владимир Александрович Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
ES2132855T3 (es) 1995-09-07 1999-08-16 Oreal Extracto de iridaceas y composiciones que lo contienen.
EA000885B1 (ru) 1996-02-12 2000-06-26 Олег Ильич ЭПШТЕЙН Лекарственное средство и способ медикаментозного воздействия на организм
IL118096A0 (en) 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
RU2104032C1 (ru) 1997-03-11 1998-02-10 Общество с ограниченной ответственностью "Снежный барс" Способ усиления лечебного эффекта лекарственных средств
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
DE19746868A1 (de) 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
RU2122858C1 (ru) 1997-12-29 1998-12-10 Яковлева Людмила Борисовна Гомеопатическое лекарственное средство седативного действия "вернисон"
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
RU2187334C2 (ru) 1998-05-22 2002-08-20 Эпштейн Олег Ильич Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2144370C1 (ru) 1999-01-06 2000-01-20 Титиева Наталья Михайловна Гомеопатическое лекарственное средство для лечения гипертрофии предстательной железы
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2177795C1 (ru) 2001-02-15 2002-01-10 Эпштей Олег Ильич Гомеопатическое лекарственное средство для лечения и профилактики аденовирусных инфекций у детей
RU2192882C1 (ru) 2001-04-18 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2199345C1 (ru) 2001-12-26 2003-02-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции углеводного и жирового обмена
UA76638C2 (en) * 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76640C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
TWI345470B (en) 2003-03-14 2011-07-21 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
RU2253478C1 (ru) 2003-10-01 2005-06-10 Эпштейн Олег Ильич Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества
KR20060125849A (ko) 2004-01-20 2006-12-06 아스텔라스세이야쿠 가부시키가이샤 발기부전 치료 방법
WO2006024673A1 (en) 2004-09-03 2006-03-09 Chr. Hansen A/S Fermented milk or vegetable proteins comprising receptor ligand and uses thereof
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
MX2008012549A (es) 2006-04-04 2009-01-14 Dong A Pharm Co Ltd Agente para la prevencion y tratamiento de hiperplasia prostatica que comprende compuesto de pirazolopirimidinona.
JP5687425B2 (ja) 2006-06-06 2015-03-18 オレグ イリッチ エプシュテイン 肥満、真性糖尿病及び耐糖能異常を伴う疾患の治療用薬剤
RU2438707C2 (ru) 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
KR100927958B1 (ko) 2006-07-13 2009-11-24 주식회사 머젠스 금속의 흡수를 촉진시키는 금속-산성아미노산 킬레이트를함유하는 조성물
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
US20130189707A1 (en) 2010-01-26 2013-07-25 Svetlana Alexandrovna Sergeeva Method of determination of autoantibody level by means of enzyme immunoassay
AU2011287288A1 (en) 2010-07-15 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
GB2495885B (en) 2010-07-15 2017-11-22 Iliich Epshtein Oleg Combination pharmaceutical composition and methods of treating genitourinary system disorders
DE112011102356T5 (de) 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit dem Herz-Kreislauf-System in Verbindung stehen
EP2593138A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
ES2542042R1 (es) 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
AU2011278038B2 (en) * 2010-07-15 2017-02-02 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
ITTO20110632A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Metodo per trattare il disturbo da deficit di attenzione e iperattivita'
US20120258146A1 (en) * 2010-07-21 2012-10-11 Oleg Iliich Epshtein Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy
FR2962912A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association destinee a etre utilisee dans un procede pour traiter la maladie d'alzheimer
WO2012010974A2 (en) * 2010-07-21 2012-01-26 Oleg Lliich Epshtein Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
WO2012010973A2 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
MX2013000804A (es) * 2010-07-21 2013-10-28 Oleg Iliich Epshtein Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos.
RU2535033C2 (ru) 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2517084C2 (ru) 2010-08-06 2014-05-27 Олег Ильич Эпштейн Способ и средство для ингибирования продукции или усиления элиминации белка р24
RU2535034C2 (ru) 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
FR2963563A1 (fr) 2010-08-06 2012-02-10 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter et prevenir les maladies infectieuses
US20120263725A1 (en) 2010-08-06 2012-10-18 Epshtein Oleg Iiiich Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
US20130171161A1 (en) 2010-12-23 2013-07-04 Oleg Iliich Epshtein Method and composition for the treatment of diseases caused by or associated with hiv
JP5418549B2 (ja) * 2011-07-06 2014-02-19 アイシン精機株式会社 車両のドアアウタハンドル装置

Also Published As

Publication number Publication date
GB201302649D0 (en) 2013-04-03
FI20135143L (fi) 2013-02-15
BR112013000840A2 (pt) 2016-06-07
JP2013538186A (ja) 2013-10-10
LT2013016A (lt) 2013-11-25
FR2962656A1 (fr) 2012-01-20
PE20130398A1 (es) 2013-04-10
GB2495884A (en) 2013-04-24
LT5988B (lt) 2014-01-27
DK201370079A (en) 2013-02-14
NO20130222A1 (no) 2013-03-22
US9308275B2 (en) 2016-04-12
EE201300006A (et) 2013-08-15
WO2012007845A3 (en) 2012-03-29
AU2011278038A1 (en) 2013-03-07
SG187038A1 (en) 2013-02-28
US20140079696A1 (en) 2014-03-20
ES2440393A2 (es) 2014-01-28
AR082247A1 (es) 2012-11-21
EP2593140A2 (en) 2013-05-22
WO2012007845A2 (en) 2012-01-19
DE112011102358T5 (de) 2013-04-25
MX2013000543A (es) 2013-10-28
CZ2013105A3 (cs) 2013-05-22
ES2440393R1 (es) 2014-10-10
GB2495884B (en) 2017-05-31
US20160244531A1 (en) 2016-08-25
US20160251448A1 (en) 2016-09-01
EA201300126A1 (ru) 2013-12-30
NZ606767A (en) 2015-08-28
EA030566B1 (ru) 2018-08-31
SG10201505561TA (en) 2015-08-28
CA2804966A1 (en) 2012-01-19
KR20140014059A (ko) 2014-02-05
AU2011278038B2 (en) 2017-02-02
JP2016216483A (ja) 2016-12-22

Similar Documents

Publication Publication Date Title
IL255300A0 (en) Antibodies to matrix metalloproteinase 9 (mmp9)
BR112014006703A8 (pt) "pirrolobenzodiazepinas
ZA201404483B (en) Improvements in or relating to the encapsulation of perfumes
BR112012022750A2 (pt) "método de produção de radionuclídeos"
BR302012001937S1 (pt) "configuração aplicada em para-lama"
ITTO20110639A1 (it) Metodo per aumentare l'effetto di una forma attivata-potenziata di un anticorpo
BR112012018086A2 (pt) método para gerar vapor d'água
ITTO20110633A1 (it) Metodo per trattare il morbo di alzheimer
PL2797845T3 (pl) Poprawianie skuteczności kwasów nadtlenowych
BR112013000225A2 (pt) ''processo''
SMT201400106B (it) Inibitori di met per incrementare l'efficacia della radioterapia
BR112013014966A2 (pt) composto aricíclico contínuo
BR112012032671A2 (pt) "processo"
ITRM20120277A1 (it) Procedimento per ridurre la larghezza di incrinature.
BR112013010195A2 (pt) "empanque"
BR112012029363A2 (pt) 'método para produção de 1-alquil-3-difluormetil-5-hidroxipirazóis'
EE201000051A (et) Suure t””pingega mitmeelemendiline superkondensaator
SM201000062A (it) Processo per la preparazione di gabapentin
IT1405433B1 (it) "un metodo per la realizzazione di una poltrona sacco"
FR2971446B3 (fr) Coiff'rasoir
TH115140B (th) เสาสำเร็จรูป
ITNU20110002U1 (it) Il cubo "mb 54"
IT1403490B1 (it) Dispositivo per la produzione di neve artificiale
IT1402305B1 (it) Dispositivo per la produzione di neve artificiale
IT1406955B1 (it) Metodo per aumentare l'efficienza di scrittura in nanodispositivi mram